Increased fragmentation of urinary fibronectin in cancer patients detected by immunoenzymometric assay using domain-specific monoclonal antibodies.
Monoclonal antibodies (MoAbs) recognizing the distinct domains of human fibronectin had previously been established and they were used to construct several sandwich immunoenzymometric assays (IEMAs) for the structural analysis of fibronectin found in the urine of cancer patients. Urinary fibronectin (UFN) was immunodetectable only with FN12-8 and FN30-8 MoAbs against cell-binding domains and was less reactive with other IEMAs using MoAbs directed to terminal domains, indicating that UFN was almost completely fragmented and consisted mainly of cell-binding regions. The IEMA using MoAbs against cell-binding domains had sufficient immunoreactivities with the antigen fragmented by artificial proteolysis, but these fragments could hardly be detected by other IEMAs. UFN levels were significantly elevated in various cancer patients and extremely elevated in some patients with distant metastasis. It is presumed that UFN fragments which increase in cancer patients are generated by extracellular matrix destruction. Thus UFN levels and the ratio of the fragmented UFN level to the non-fragmented UFN level appear to be informative clinical indicators of tumor malignancy or metastatic ability in cancer patients.
Katayama
M
M
Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., Shiga, Japan.
Kamihagi
K
K
Nakagawa
K
K
Akiyama
T
T
Sano
Y
Y
Ouchi
R
R
Nagata
S
S
Hino
F
F
Kato
I
I
D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D014408:Biomarkers, Tumor / Q000652:urine; D005353:Fibronectins / Q000097:blood / Q000276:immunology / Q000652:urine*; D006801:Humans; D007124:Immunoenzyme Techniques; D051379:Mice; D009369:Neoplasms / Q000652:urine*; D010446:Peptide Fragments / Q000652:urine
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D005353:Fibronectins; D010446:Peptide Fragments